BALTIMORE, MD -- (Marketwired) -- 06/17/13 -- Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, reports that the remarkable median survival and one-year survival data from the Company's Phase II pancreatic cancer clinical trials will emerge as Nuvilex Inc.'s (OTCQB: NVLX) trump card. The Company is an international firm engaged in using its live-cell encapsulation technology as part of treatments for pancreatic and other cancers along with the development of therapies based on components of medical marijuana for the treatment of oncology patients.
Given that there is no cure for pancreatic cancer, the key endpoint and objective on behalf of patients given various therapies and treatments is to increase the amount of time a patient treated with therapy will survive as a result of the treatment. Perhaps this is why even fair results are led with cheers and adulation. For example, the current gold standard and only approved treatment that is used today, Gemzar®, has demonstrated a one year survival rate of 18% and a median overall survival rate of 6.7 months. Conversely, ABRAXANE®, developed by Celgene, released its Phase III results in early 2013 to much fanfare as it demonstrated statistical improvement over Gemzar® alone.
Still, this data pales in comparison to that of Nuvilex's Phase II trials. In the Nuvilex Phase II pancreatic cancer trials in which its technology was used to encapsulate live cancer-drug-activating cells which were then implanted near the pancreas and therefore the tumor, the anticancer drug ifosfamide was administered. Median survival nearly doubled (13 months vs. 6.7 months) and one-year survival doubled from 18% to 36%, as compared to historical data for Gemzar®, the only drug approved to date by the FDA as a single agent for the treatment of advanced inoperable pancreatic cancer.
For those keeping score, Celgene's lauded drug increased overall survival by 27%, while Nuvilex increased median survival by nearly 100%. The one-year survival rate was increased by 59% for Celgene and 100% for Nuvilex. Granted, ABRAXANE® has been approved for other cancers and the data is from a Phase III trial. Nonetheless, if Nuvilex were to generate its previous results in a Phase III trial, the Company would likely be the oncology treatment story of the year.
A copy of this article as well as other articles and Nuvilex reports and disclaimers can be accessed by visiting www.goldmanresearch.com.
About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces small cap and micro cap stock research reports, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.
A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.
About Nuvilex, Inc. (OTCQB: NVLX): Nuvilex, Inc. has been a provider of all-natural products for many years, has expanded its company to increase its natural product based footprint through medical marijuana studies and is becoming an international biotechnology provider of live, therapeutically valuable, encapsulated cells and services for treatments, research and medicine. The Company's offerings will ultimately include cancer, diabetes and other clinical treatments using the company's natural product knowledge, product base, cell and gene therapy expertise, and live-cell encapsulation technology in addition to other new products currently under development. For more information visit: www.nuvilex.com.
Goldman Small Cap Research
Most Popular Stories
- Small Businesses Could Get Paid Faster
- Challenger Raises Bar on Muscle Cars
- Correction: North Dakota Saltwater Spill Story
- Perez Picks Heavily Hispanic Districts in Recount
- Infiniti Exec de Nysschen to Head Cadillac
- Economists Sharply Cut Forecasts for U.S. Growth
- Fight Against Teacher Tenure Gains Momentum
- NHTSA Probes Ford Steering Problems
- Reynolds, Lorillard in Merger Talks
- Downside of Low Mortgage Rates: Less Selling